Table 1 Baseline and disease characteristics by dosing group
Part A | Part B | Total (n = 33) | |||||
|---|---|---|---|---|---|---|---|
0.3 mg/kg (n = 4) | 1 mg/kg (n = 3) | 3 mg/kg (n = 7) | 10 mg/kg (n = 5) | 10 mg/kg without oral iron (cohort B1) (n = 7) | 10 mg/kg with oral iron (cohort B2) (n = 7) | ||
Age, years | 64.5 (58–75) | 76.7 (63–88) | 62.1 (44–78) | 63.2 (53–75) | 66.3 (50–79) | 62.7 (51–72) | 64.9 (44–88) |
Sex | |||||||
Men | 2 (50) | 2 (67) | 3 (43) | 2 (40) | 3 (43) | 1 (14) | 13 (39) |
Women | 2 (50) | 1 (33) | 4 (57) | 3 (60) | 4 (57) | 6 (86) | 20 (61) |
Race | |||||||
White | 4 (100) | 3 (100) | 5 (71) | 3 (60) | 5 (71) | 5 (71) | 25 (76) |
Black or African American | 0 | 0 | 2 (29) | 1 (20) | 2 (29) | 2 (29) | 7 (21) |
Asian | 0 | 0 | 0 | 1 (20) | 0 | 0 | 1 (3) |
ECOG performance status | |||||||
0 | 1 (25) | 1 (33) | 2 (29) | 0 | 0 | 0 | 4 (12) |
1 | 3 (75) | 2 (67) | 3 (43) | 5 (100) | 7 (100) | 6 (86) | 26 (79) |
2 | 0 | 0 | 2 (29) | 0 | 0 | 1 (14) | 3 (9) |
Prior cancer treatment | |||||||
Systemic chemotherapy | 4 (100) | 3 (100) | 7 (100) | 5 (100) | 5 (71) | 4 (57) | 28 (85) |
Radiotherapy | 1 (25) | 1 (33) | 2 (29) | 3 (60) | 2 (29) | 5 (71) | 14 (42) |
Surgery | 3 (75) | 1 (33) | 2 (29) | 2 (40) | 1 (14) | 2 (29) | 11 (33) |
Median no. of prior oncology treatments | 9.5 | 4.0 | 6.0 | 5.0 | 2.0 | 1.5 | 4.5 |
Mean serum hepcidin (ng/mL) | 24.9 (18.51) | 12.2 (8.48) | 36.4 (21.87) | 51.1 (39.81) | 45.4 (20.23) | 39.7 (38.99) | 37.6 (28.46) |
Mean hemoglobin (g/dL) | 9.1 (1.45) | 8.9 (0.91) | 8.5 (0.83) | 9.8 (0.84) | 9.4 (1.13) | 9.5 (0.31) | 9.2 (0.95) |
Mean erythropoietin (mIU/mL) | 141.3 (92.71) | 42.0 (20.16) | 103.2 (135.14) | 94.4 (116.49) | 70.0 (60.87) | 46.1 (25.67) | 81.8 (88.29) |
Mean serum ferritin (μg/L) | 779.0 (303.64) | 237.2 (136.68) | 667.1 (683.65) | 263.7 (178.90) | 714.6 (553.58) | 289.0 (175.70) | 510.3 (464.15) |
Cancer type | |||||||
Multiple myeloma | 1 (25) | 0 | 2 (29) | 3 (60) | 3 (43) | 3 (43) | 14 (42) |
Breast cancer | 0 | 0 | 0 | 1 (20) | 3 (43) | 0 | 4 (12) |
Othera | 3 (75) | 3 (100) | 5 (71) | 1 (20) | 1 (14) | 4 (57) | 15 (46) |